Antispam
CyTuVax has shown the strength of its vaccine adjuvant technology in the Phase 2 clinical trial of a vaccine for hepatitis B non-responders Press release 17-06-2019
CyTuVax B.V.Oxfordlaan 55 6229 EV MaastrichtThe Netherlands
+31-433881424Contact us by email
CyTuVax has shown the strength of its vaccine adjuvant technology in the Phase 2 clinical trial of a vaccine for hepatitis B non-responders